Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0358 • ACR Convergence 2024
Residual’ Fatigue and Its Severity in Patients with Rheumatoid Arthritis in Clinical Remission: Prevalence and Associated Factors
Rosa Maria Morlà Novell¹, Beatriz Frade-Sosa², Lola Tobalina Maestre³, Meritxell Sallés Lizarzaburu⁴, Virginia Ruiz-Esquide², Maria López Lasanta⁵, Georgina Salvador Alarcón⁶, Noemí Busquets Pérez⁷, Marta Valls Roc⁸, Enrique Gonzalez Dávila⁹, Jose Alfredo Gomez-Puerta¹⁰ and Raimon Sanmartí Sala¹⁰, and ARCat study Group, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Clinic de Barcelona, Barcelona, Spain, ³Fundació Clinic per la Recerca clínica, Barcelona, Spain, ⁴Althaia Xarxa Assistencial Universitària Manresa, Manresa, Catalonia, Spain, ⁵Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, ⁶Hospital Mútua de Terrassa, Terrassa, Spain, ⁷HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ⁸Hospital Universitari Josep Trueta, Girona, ⁹Universidad de La Laguna, Santa Cruz de Tenerife, Spain, ¹⁰Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: Fatigue is a frequent and annoying symptom in rheumatoid arthritis (RA) patients that is often not assessed at routine follow-up visits. Residual’ fatigue has…
Abstract Number: 0458 • ACR Convergence 2024
Long-Term Outcomes in Seronegative Rheumatoid Arthritis
Bradly Kimbrough¹, Cynthia Crowson², Sara Achenbach³ and Elena Myasoedova², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Seronegative rheumatoid arthritis (RA) is a heterogenous disease distinct from seropositive RA regarding genetic risk factors, pathobiology, and prognosis. Notably, recent studies have shown…
Abstract Number: 0474 • ACR Convergence 2024
Association Between Rheumatoid Arthritis and Survival After Cancer: A Systematic Literature Review and Meta-analysis
Joshua Hsieh¹, Avneet Kaur², Hemant Khandelia³, Teresa Jewell⁴, Aman Singh⁵, Lauren Barkley⁶, Ishan Bansal⁷, Simmi Oberoi⁸ and Namrata Singh⁹, ¹Lakeside High School, Seattle, WA, ²SUNY Upstate, Buffalo, NY, ³AIIMS, New Delhi, Delhi, India, ⁴University of Washington, Seattle, WA, ⁵Rajindra Hospital, Patiala, Punjab, India, ⁶Brandeis University, Boston, MA, ⁷Yale University, New Haven, CT, ⁸Rajindra Hospital, New Delhi, India, ⁹University of Washington, Bellevue, WA
Background/Purpose: Increasing evidence suggests that inflammation, a hallmark of rheumatoid arthritis (RA), is associated with an elevated risk of cancer and can influence cancer outcomes.…
Abstract Number: 0492 • ACR Convergence 2024
A Machine Learning Model for the Early Identification of Rheumatoid Arthritis: Development and Validation
Michael Dreyfuss¹, Yonatan Jenudi², Dan Riesel³, Or Ramni³, Daniel Underberger⁴, Benjamin Getz⁵, Shlomit Steinberg-Koch³, Douglas White⁶ and Elena Myasoedova⁷, ¹Predicta Med, Ramat Gan, Israel, ²[email protected], Ramat Gan, Israel, ³Predicta Med Analytics Ltd., Ramat Gan, Israel, ⁴Predicta Med Analytics Ltd., Bridgeport, CT, ⁵CTO, Ramat Gan, Israel, ⁶Gundersen Health System, Onalaska, WI, ⁷Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis often experience clinically significant delays in diagnosis (Sørensen et al., 2015; Raza et al., 2011). RA can present similarly to…
Abstract Number: 0508 • ACR Convergence 2024
Real-World Evidence for GP2015 in Patients with Rheumatoid Arthritis: Safety Outcomes from German Observational Data
Xenofon Baraliakos¹, Cristofer Salvati², Elena Bachinskaya², Samriddhi Sinha² and Klaus Krüger³, ¹Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ²Medical Affairs, Sandoz Hexal AG, Holzkirchen, Germany, Holzkirchen, Germany, ³Rheumatologisches Praxiszentrum, Munich, Germany, München, Germany
Background/Purpose: GP2015 is an etanercept biosimilar indicated for the treatment of rheumatoid arthritis (RA).1 The objective of this abstract is to describe the baseline characteristics…
Abstract Number: 0525 • ACR Convergence 2024
Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial
Varun Dhir¹, Harshith Sai Koneti², Aman Sharma³, sanjay jain⁴ and shankar naidu⁵, ¹PGIMER, CHD, INDIA, CHANDIGARH, India, ²PGIMER, Chandigarh, Sangareddy, Telangana, India, ³PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, ⁴PGIMER, Chandigarh, Chandigarh, India, ⁵PGIMER, Chandigarh, India, Chandigarh, India
Background/Purpose: : Methotrexate (MTX) Intolerance continues to occur in 20-40% patients despite low-dose folic acid (5-10mg per week) supplementation. Would a higher dose of folic…
Abstract Number: 0796 • ACR Convergence 2024
Development and Evaluation of Machine Learning Prediction Models for Hospitalizations Due to Opioid-Related Harms Among New Users with Rheumatic and Musculoskeletal Diseases
Carlos Raul Ramirez Medina¹, Mark Lunt², David Jenkins², William Dixon², Niels Peek³ and Meghna Jani², ¹The University of Manchester, Warrington, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³THIS Institute , University of Cambridge, Cambridge, United Kingdom
Background/Purpose: England has seen a notable rise in prescription opioid use over the past two decades, leading to some of Europe's highest opioid-related hospital admissions.…
Abstract Number: 0883 • ACR Convergence 2024
The Study of 62 Circulating Soluble Factors Is Able to Predict the Lack of Response to MTX Treatment in Recently Diagnosed DMARD Naïve Rheumatoid Arthritis Smoker and Non-Smoker Patients
Jorge Monserrat¹, Cristina Bohorquez², Ana Maria Gómez³, Elena Rabadán Rubio⁴, Raquel Sánchez³, Atusa Movasat⁵, Lucia Ruiz⁴, Fernando Albarran Hernandez⁶, Miguel Ángel Ortega¹, Ana Perez⁶ and Melchor Alvarez-Mon⁷, ¹Universidad de Alcalá. IRYCIS, Alcalá de Henares, Madrid, Spain, ²Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain, ³Universidad de Alcalá, Alcalá de Henares, Madrid, Spain, ⁴Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain, ⁵Hospital Universitario Príncipe de Asturias, Madrid, Spain, ⁶Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ⁷Universidad de Alcalá. HUPA. IRYCIS, Madrid, Spain

Background/Purpose: Rheumatoid arthritis (RA) is a highly inflammatory severe chronic autoimmune disorder with an inadequate activation of the immune cells. These cells are responsible for…
Abstract Number: 0940 • ACR Convergence 2024
Trans-endothelial Migration of Synovial Fibroblasts Promotes Arthritis Severity Through a PKD1-mediated Feedback Loop
Jaeyeon Kim, Richard Ainsworth and Nunzio Bottini, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: The application of single cell genomic approaches to the study of rheumatoid synovium has recently enabled scientists to study the complex relationship between different…
Abstract Number: 1006 • ACR Convergence 2024
Associations Between Rheumatic Diseases and Mental Health Disorders
Thoai Vu, Sivam Bhatt and Janet Lewis, University of Virginia, Charlottesville, VA
Background/Purpose: Rheumatic diseases are frequently linked to a reduced quality of life (QoL), particularly as disease severity escalates. Patients with rheumatic conditions often exhibit high…
Abstract Number: 1048 • ACR Convergence 2024
Self-Perception of Oral Health and Habits in Patients with Sjögren’s Syndrome, Rheumatoid Arthritis, and Systemic Lupus Erythematosus
Karina Palomo-Arnaud¹, Gabriel Figueroa-Parra², Angel Kevin Garza-Elizondo¹, Margarita Isabel Alarcon Jarquin³, Jesus Cardenas-de la Garza⁴, Dionicio Galarza-Delgado⁵ and Janett Riega Torres², ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁴Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁵UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Oral manifestations, especially periodontitis and tooth loss, are highly prevalent in patients with rheumatic diseases. Sjogren’s syndrome (SS), rheumatoid arthritis (RA), and systemic lupus…
Abstract Number: 1324 • ACR Convergence 2024
Rheumatoid Arthritis Associated Interstitial Lung Disease – Patient Perceptions and Recommendations
Shirish Dubey¹, Abhinav Peddasomayajula², Damodar Makkuni³, Anupama Nandagudi⁴, Win Win Maw⁵ and Gouri M Koduri⁶, ¹Oxford University Hospitals NHS FT, Oxford, United Kingdom, ²Mid and South Essex NHS Foundation Trust, Southend, England, United Kingdom, ³James Paget University Hospital NSH FT, Great Yarmouth, United Kingdom, ⁴MSEFT, Basildon, United Kingdom, ⁵Mid and South Essex NHS Foundation Trust, Chelmsford, England, United Kingdom, ⁶Southend Univeristy Hospitals NHS Trust, Essex, United Kingdom
Background/Purpose: Interstitial lung disease (ILD) is one of the complications of rheumatoid arthritis (RA) and has significant impact on morbidity and mortality. RA significantly reduces…
Abstract Number: 1341 • ACR Convergence 2024
Evaluation of Width Range Index (WRI) and Neutrophil-to-Lymphocyte Ratio (NLR) in Assessing Disease Activity in Patients with Rheumatoid Arthritis
Santiago Dans Caballero¹, Marta Rojas Giménez², Clementina López Medina³, Andrea Cid Chaves², Mónica Rico-Muñoz³, mitndbaim aelohim parra Moreno² and Alejandro Escudero-Contreras⁴, ¹Reina Sofia University Hospital, Lebrija, Andalucia, Spain, ²Reina Sofia University Hospital, Cordoba, Andalucia, Spain, ³Reina Sofia University Hospital, Cordoba, Spain, ⁴Reina Sofia University Hospital, Córdoba, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory condition characterized by joint inflammation and systemic involvement. In this preliminary study, we explore the potential link…
Abstract Number: 1357 • ACR Convergence 2024
Kidney Function in Rheumatoid Arthritis: Estimating Glomerular Filtration Rate Using Creatinine versus Cystatin C in a Secondary Analysis of the TARGET Trial
Sho Fukui¹, Lesley Inker², Leah Santacroce³, Jon Giles⁴, Katherine Liao³, Joan Bathon⁵ and Daniel Solomon⁶, ¹Brigham and Women's Hospital, Brookline, MA, ²Tufts Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Cedars Sinai Medical Center, Los Angeles, CA, ⁵Columbia University, NEW YORK, NY, ⁶Brigham and Women's Hospital, Newton, MA
Background/Purpose: Glomerular filtration rate (GFR) is difficult to measure in patients with RA since creatinine-based estimated glomerular filtration rate (eGFRcr) may overestimate GFR due to…
Abstract Number: 1373 • ACR Convergence 2024
The Effect of Methotrexate on Lipid and Apolipoprotein Levels in RA Goes Hand-in-hand with EULAR Response
Varun Dhir¹, Chandra Bhushan Prasad², Siddharth Jain³, shankar naidu⁴, Aman Sharma⁵, Shefali Sharma⁶, Indu Verma⁷ and sanjay jain⁸, ¹PGIMER, CHD, INDIA, CHANDIGARH, India, ²Healthway Hospital, Goa, India, Zuarinagar, Goa, India, ³All India Institute of Medical Sciences, New Delhi, Delhi, Delhi, India, ⁴PGIMER, Chandigarh, India, Chandigarh, India, ⁵PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, ⁶Government, Chandigarh, Chandigarh, India, ⁷PGIMER, Chandigarh, India, ⁸PGIMER, Chandigarh, Chandigarh, India
Background/Purpose: Methotrexate improves cardiovascular risk in autoimmune inflammatory diseases like RA, and has been shown to suppress inflammation and increase lipid levels. However, it is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].